Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q4834702> ?p ?o }
Showing triples 1 to 39 of
39
with 100 triples per page.
- Q4834702 subject Q7486806.
- Q4834702 subject Q8761830.
- Q4834702 subject Q8919936.
- Q4834702 subject Q9052323.
- Q4834702 subject Q9601368.
- Q4834702 abstract "BAY 73-6691 is a drug developed by Bayer for the treatment of Alzheimer's disease. It was the first compound developed that acts as a phosphodiesterase inhibitor selective for the PDE9A subtype. The PDE9A enzyme is expressed primarily in the brain, with high concentrations in the cerebellum, neocortex, striatum, and hippocampus, and acts to limit the cGMP-mediated signal transduction which occurs following glutamate binding to NMDA receptors. Consequently, selective PDE9A inhibitors were predicted to prolong intracellular responses to glutamate and enhance glutamate signalling, and since this process is known to be involved in learning and memory, PDE9A inhibitors should have a nootropic effect and may be useful in the treatment of Alzheimer's.Animal studies have confirmed these expectations, and BAY 73-6691 has been shown to improve learning and memory in rats. As the first selective PDE9A inhibitor to be developed, it is also widely used in research into the function of this enzyme subtype. However pre-clinical research is at an early stage and it is not yet known whether BAY 73-6691 will prove suitable to progress to human trials, or if it will remain merely a laboratory research tool.".
- Q4834702 casNumber "794568-92-6".
- Q4834702 iupacName "1-(2-chlorophenyl)-6-[(2R)-3,3,3-trifluoro-2-methylpropyl]-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidine-4-one".
- Q4834702 pubchem "16078952".
- Q4834702 thumbnail BAY73-6691_structure.png?width=300.
- Q4834702 wikiPageWikiLink Q11081.
- Q4834702 wikiPageWikiLink Q130983.
- Q4834702 wikiPageWikiLink Q1319792.
- Q4834702 wikiPageWikiLink Q152051.
- Q4834702 wikiPageWikiLink Q18030418.
- Q4834702 wikiPageWikiLink Q181136.
- Q4834702 wikiPageWikiLink Q414896.
- Q4834702 wikiPageWikiLink Q418251.
- Q4834702 wikiPageWikiLink Q422511.
- Q4834702 wikiPageWikiLink Q48360.
- Q4834702 wikiPageWikiLink Q726562.
- Q4834702 wikiPageWikiLink Q742487.
- Q4834702 wikiPageWikiLink Q7486806.
- Q4834702 wikiPageWikiLink Q828130.
- Q4834702 wikiPageWikiLink Q8761830.
- Q4834702 wikiPageWikiLink Q8919936.
- Q4834702 wikiPageWikiLink Q9052323.
- Q4834702 wikiPageWikiLink Q9601368.
- Q4834702 casNumber "794568".
- Q4834702 iupacName "1".
- Q4834702 pubchem "16078952".
- Q4834702 type ChemicalSubstance.
- Q4834702 type Drug.
- Q4834702 type ChemicalObject.
- Q4834702 type Thing.
- Q4834702 type Q8386.
- Q4834702 comment "BAY 73-6691 is a drug developed by Bayer for the treatment of Alzheimer's disease. It was the first compound developed that acts as a phosphodiesterase inhibitor selective for the PDE9A subtype. The PDE9A enzyme is expressed primarily in the brain, with high concentrations in the cerebellum, neocortex, striatum, and hippocampus, and acts to limit the cGMP-mediated signal transduction which occurs following glutamate binding to NMDA receptors.".
- Q4834702 label "BAY 73-6691".
- Q4834702 depiction BAY73-6691_structure.png.